|
Acorda Therapeutics CEO Ron Cohen (left), Icahn Institute for Genomics and Multiscale Biology director Eric Schadt (middle), and Rockefeller University president Marc Tessier-Lavigne (right) gave the audience a snapshot of the past, present, and future of New York biotech.
Ok, New York City's now a hotbed for wide-ranging academic collaborations, but it didn't used to be that way. What's changed?
Meg Tirrell (Bloomberg) and Alex Denner (Sarissa Capital Management) engage in some lighter moments with the crowd.
Celgene's senior vice president of business development, George Golumbeski (left), gives some candid thoughts about the mindset at Celgene: "It's deep in the DNA there to take a risk and think outside the box," he says. Francois Nader, who completely overhauled NPS Pharma to keep it alive, looks on.
A true New York biotech cluster is coming. It’s just going to take some more disruption to get there.
That was one of the big themes I took home when I recapped our latest Big Apple biotech event, “New York’s Life Science Disruptors,” on Monday. The event, which took place last Thursday, March 6, consisted of a lively series of discussions about the state of biotech in the big city, featuring viewpoints from different key contributors to the life sciences ecosystem: academics/researchers, industry players, and investors. Today, I’m circling back with a slideshow look into what was a fun night on East 29th Street (a big thank you to Hana & LaCruz for the photos).
Once again, a special thanks to our speakers and moderators, our event host Alexandria Real Estate Equities, and our sponsors: Halloran Consulting Group and Guard Dog Brand Development.
Ben Fidler is Xconomy's Deputy Biotechnology Editor. You can e-mail him at bfidler@xconomy.com Follow @benthefidler
By posting a comment, you agree to our terms and conditions.
Xconomy Insight · Webinar
Join us for this exclusive FREE webinar!
Sponsored · Whitepaper
Investing in growth will continue to power the IT M&A cycle going forward
RSMSponsored · Whitepaper
Understand who’s affected, what’s changed, and the impact on your business with the Labor Department's 'final rule' requirements for financial disclosures.
DocuSignThe Hidden Risks of Sourcing Human Biological Samples
Scientist.comBusiness, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit/Ann Arbor, San Francisco, New York, Raleigh-Durham, Boulder/Denver, Texas, Wisconsin, Indiana, and beyond.
© 2007-2018, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.
Website development support from Andrew Koyfman with design support from Rob Hunter.